The comparison of thrombocytosis and platelet-lymphocyte ratio as potential prognostic markers in colorectal cancer

Summary

The aim of the present study was to analyse the preoperative platelet count and the platelet-lymphocyte ratio (PLR) in patients with colorectal cancer (CRC) of different stages and with hepatic metastasis of CRC (mCRC) and to compare these factors as potential prognostic markers. Clinicopathological data of 10 years were collected retrospectively from 336 patients with CRC and 118 patients with mCRC. Both in the CRC and the mCRC group overall survival (OS) was significantly worse in patients who had elevated platelet count (hazard ratio [HR] = 2.2, p < 0.001 and HR = 2.9, p = 0.018, respectively). Multivariate analysis indicated that elevated platelet count was an independent prognostic factor of CRC (HR = 1.7, p = 0.035) and mCRC (HR = 3.1, p = 0.017). Disease-free survival (DFS) was significantly worse in patients with elevated platelet count in the CRC group (HR = 2.0, p = 0.011). In the multivariate analysis the PLR was not a prognostic factor in either of the two cohorts (HR = 0.92, p < 0.001 and HR = 0.89, p = 0.789, respectively). The platelet count is a valuable prognostic marker for the survival in patients both with CRC and mCRC while the PLR is not prognostic in either group.

Keywords

Platelet-lymphocyte ratio - thrombocytosis - colorectal cancer - survival

^* Equal first authors of the manuscript.

• References

• 1 Parkin DM, Bray F, Ferlay J. et al. Global cancer statistics 2002. CA Cancer J Clin 2005; 55: 74-108.
• 2 Xu R, Zhou B, Fung PC. et al. Recent advances in the treatment of colon cancer. Histopathol 2006; 21: 867-872.
• 3 McArdle CS, Hole DJ. Outcome following surgery for colorectal cancer: analysis by hospital after adjustment for case-mix and deprivation. Br J Cancer 2002; 86: 331-335.
• 4 Graziano F, Cascinu S. Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes’ B colorectal cancer patients: how much evidence is enough?. Ann Oncol 2003; 14: 1026-1038.
• 5 McMillan DC, Crozier JE, Canna K. et al. Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis 2007; 22: 881-886.
• 6 Hernandez E, Lavine M, Dunton CJ. et al. Poor prognosis associated with thrombocytosis in patients with cervical cancer. Cancer 1992; 69: 2975-2977.
• 7 Ikeda M, Furukawa H, Imamura H. et al. Poor prognosis associated with throm-bocytosis in patients with gastric cancer. Ann Surg Oncol 2002; 9: 287-291.
• 8 Assoian RK, Sporn MB. Type beta transforming growth factor in human platelets: release during platelet degranulation and action on vascular smooth muscle cells. J Cell Biol 1986; 102: 1217-1223.
• 9 Dubernard V, Arbeille BB, Lemesle MB. et al. Evidence for an alpha-granular pool of the cytoskeletal protein alpha-actinin in human platelets that redistributes with the adhesive glycoprotein thrombospondin-1 during the exocy-totic process. Arterioscler Thromb Vasc Biol 1997; 17: 2293-2305.
• 10 Kaplan KL, Broekman MJ, Chernoff A. et al. Platelet alpha-granule proteins: studies on release and subcellular localisation. Blood 1979; 53: 604-618.
• 11 Verheul HM, Hoekman K, Lupu F. et al. Platelet and coagulation activation with vascular endothelial growth factor generation in soft tissue sarcomas. Clin Cancer Res 2000; 6: 166-171.
• 12 Banks RE, Forbes MA, Kinsey SE. et al. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer 1998; 77: 956-964.
• 13 Gupta GP, Massague J. Platelets and metastasis revisited: a novel fatty link. J Clin Invest 2004; 114: 1691-1693.
• 14 Tsuruo T, Fujita N. Platelet aggregation in the formation of tumour metastasis. Proc Jpn Acad Ser B Phys Biol Sci 2008; 84: 189-198.
• 15 Folman CC, Linthorst GE, van Mourik J. et al. Platelets release thrombopoietin (Tpo) upon activation: another regulatory loop in thrombocytopoiesis?. Thromb Haemost 2000; 83: 923-930.
• 16 Medinger M, Tzankov A, Kern J. et al. Increased Dkk3 protein expression in platelets and megakaryocytes of patients with myeloproliferative neoplasms. Thromb Haemost 2011; 105: 72-80.
• 17 Zitt M, Untergasser G, Amberger A. et al. Dickkopf-3 as a new potential marker for neoangiogenesis in colorectal cancer: expression in cancer tissue and adjacent non-cancerous tissue. Dis Markers 2008; 24: 101-109.
• 18 Nieswandt B, Hafner M, Echtenacher B. et al. DN. Lysis of tumour cells by natural killer cells in mice is impeded by platelets. Cancer Res 1999; 59: 1295-1300.
• 19 Colotta F, Allavena P, Sica A. et al. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009; 30: 1073-1081.
• 20 Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
• 21 Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2001; 357: 539-545.
• 22 Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-867.
• 23 Gunter MJ, Stolzenberg-Solomon R, Cross AJ. et al. A prospective study of serum C-reactive protein and colorectal cancer risk in men. Cancer Res 2006; 66: 2483-2487.
• 24 McMillan DC, Elahi MM, Sattar N. et al. Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer. Nutr Cancer 2001; 41: 64-69.
• 25 Walsh SR, Cook EJ, Goulder F. et al. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 2005; 91: 181-184.
• 26 Klinger MH, Jelkmann W. Role of blood platelets in infection and inflammation. J Interferon Cytokine Res 2002; 22: 913-922.
• 27 Alexandrakis MG, Passam FH, Moschandrea IA. et al. Levels of serum cytokines and acute phase proteins in patients with essential and cancer-related throm- bocytosis. Am J Clin Oncol 2003; 26: 135-140.
• 28 Proctor MJ, McMillan DC, Morrison DS. et al. A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer 2012; 107: 695-699.
• 29 Kwon HC, Kim SH, Oh SY. et al. Clinical significance of preoperative neutro-phil-lymphocyte versus platelet-lymphocyte ratio in patients with operable co-lorectal cancer. Biomarkers 2012; 17: 216-222.
• 30 He W, Yin C, Guo G, Jiang C. et al. Initial neutrophil lymphocyte ratio is superior to platelet lymphocyte ratio as an adverse prognostic and predictive factor in metastatic colorectal cancer. Med Oncol 2013; 30: 439.
• 31 Proctor MJ, McMillan DC, Morrison DS. et al. A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer 2012; 107: 695-699.
• 32 Raungkaewmanee S, Tangjitgamol S, Manusirivithaya S. et al. Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. J Gynecol Oncol 2012; 23: 265-273.
• 33 Asher V, Lee J, Innamaa A, Bali A. Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer. Clin Transl Oncol 2011; 13: 499-503.
• 34 Bensalah K, Leray E, Fergelot P. et al. Prognostic value of thrombocytosis in renal cell carcinoma. J Urol 2006; 175: 859-863.
• 35 Hernandez E, Donohue KA, Anderson LL. et al. The significance of thrombocytosis in patients with locally advanced cervical carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2000; 78: 137-142.
• 36 Taucher S, Salat A, Gnant M. et al. Impact of pretreatment thrombocytosis on survival in primary breast cancer. Thromb Haemost 2003; 89: 1098-1106.
• 37 Aoe K, Hiraki A, Ueoka H. et al. Thrombocytosis as a useful prognostic indicator in patients with lung cancer. Respiration 2004; 71: 170-173.
• 38 Monreal M, Fernandez-Llamazares J, Pinol M. et al. Platelet count and survival in patients with colorectal cancer-- a preliminary study. Thromb Haemost 1998; 79: 916-918.
• 39 Qiu MZ, Yuan ZY, Luo HY. et al. Impact of pretreatment hematologic profile on survival of colorectal cancer patients. Tumour Biol 2010; 31: 255-260.
• 40 Kandemir EG, Mayadagli A, Karagoz B. et al. Prognostic significance of throm-bocytosis in node-negative colon cancer. J Int Med Res 2005; 33: 228-235.
• 41 Sasaki K, Kawai K, Tsuno NH. et al. Impact of preoperative thrombocytosis on the survival of patients with primary colorectal cancer. World J Surg 2012; 36: 192-200.
• 42 Lin MS, Huang JX, Zhu J. et al. Elevation of platelet count in patients with colo-rectal cancer predicts tendency to metastases and poor prognosis. Hepatogas-troenterology 2012; 59: 1687-1690.
• 43 Nyasavajjala SM, Runau F, Datta S. et al. Is there a role for pre-operative throm-bocytosis in the management of colorectal cancer?. Int J Surg 2010; 8: 436-438.
• 44 Bhatti I, Peacock O, Lloyd G. et al. Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio. Am J Surg 2010; 200: 197-203.
• 45 McMillan DC, Canna K, McArdle CS. Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg 2003; 90: 215-219.
• 46 Wang DS, Ren C, Qiu MZ. et al. Comparison of the prognostic value of various preoperative inflammation-based factors in patients with stage III gastric cancer. Tumour Biol 2012; 33: 749-756.